ID   MGH164
AC   CVCL_E4DR
RX   PubMed=26828195;
CC   Characteristics: Erlotinib resistant (PubMed=26828195).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Unexplicit; Ex19del; Zygosity=Unspecified (PubMed=26828195).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Unspecified (PubMed=26828195).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C2926; Lung non-small cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 19-12-24; Last updated: 19-12-24; Version: 1
//
RX   PubMed=26828195; DOI=10.1038/nm.4040; PMCID=PMC4900892;
RA   Hata A.N., Niederst M.J., Archibald H.L., Gomez-Caraballo M.,
RA   Siddiqui F.M., Mulvey H.E., Maruvka Y.E., Ji F., Bhang H.-e.C.,
RA   Krishnamurthy Radhakrishna V., Siravegna G., Hu H.-C., Raoof S.,
RA   Lockerman E.L., Kalsy A., Lee D., Keating C.L., Ruddy D.A., Damon L.J.,
RA   Crystal A.S., Costa C., Piotrowska Z., Bardelli A., Iafrate A.J.,
RA   Sadreyev R.I., Stegmeier F., Getz G., Sequist L.V., Faber A.C.,
RA   Engelman J.A.;
RT   "Tumor cells can follow distinct evolutionary paths to become
RT   resistant to epidermal growth factor receptor inhibition.";
RL   Nat. Med. 22:262-269(2016).
//